公开(公告)号：US20240350656A1

公开(公告)日：2024-10-24

申请号：US18604709

申请日：2024-03-14

Applicant: Paul Scherrer Institut

Inventor： Philipp SPYCHER ,  Roger SCHIBLI ,  Martin BEHE ,  Jori WEHRMULLER

IPC: A61K47/68 ,  C07K16/28 ,  C07K16/32 ,  C12P21/00

CPC classification number: A61K47/6889 ,  A61K47/6803 ,  A61K47/68031 ,  A61K47/68033 ,  A61K47/6855 ,  C07K16/2878 ,  C07K16/32 ,  C12P21/00 ,  C07K2317/24 ,  C07K2317/41

Abstract: The present invention relates to a method for generating an antibody-payload conjugate by means of a microbial transglutaminase (MTG). The method comprises a step of conjugating a linker having a primary amine residue, said linker having the peptide structure (shown in N->C direction) (Aax)m-(Aax)(NH2)-(Aax)n-B-(Aax)o, or (Aax)m-B-(Aax)n-(Aax)(NH2)-(Aax)o, to a Gln residue comprised in the heavy or light chain of an antibody. Aax(NH2) is an amino acid, amino acid derivative or amino acid mimetic comprising a side chain having a primary amine group

公开(公告)号：US12110320B2

公开(公告)日：2024-10-08

申请号：US17698645

申请日：2022-03-18

Applicant: The University of North Carolina at Chapel Hill

Inventor： Samuel Lai ,  M. Gregory Forest ,  Christine Henry ,  Timothy Wessler ,  Alexander Chen ,  Jennifer Schiller ,  Jay Newby

IPC: A61K39/04 ,  A61P31/00 ,  C07K16/08 ,  C07K16/10 ,  C07K16/12 ,  C07K16/44 ,  G01N33/543 ,  G01N33/557 ,  G01N33/569 ,  G01N33/68 ,  A61K38/00

CPC classification number: C07K16/1235 ,  A61P31/00 ,  C07K16/087 ,  C07K16/1045 ,  C07K16/44 ,  G01N33/54346 ,  G01N33/557 ,  G01N33/56983 ,  G01N33/6854 ,  A61K38/00 ,  C07K2317/41 ,  G01N2333/16 ,  G01N2333/4725

Abstract: The presently-disclosed subject matter relates to crosslinkers, compositions, and methods for trapping a target of interest on a substrate of interest. The methods may be used to inhibit and treat pathogen infection and provide contraception. The methods may be used to trap or separate particles and other substances. The subject matter further relates to methods of identifying and preparing optimal crosslinkers and methods for manipulating targets of interest.

公开(公告)号：US20240327890A1

公开(公告)日：2024-10-03

申请号：US18741057

申请日：2024-06-12

Applicant: Hoffmann-La Roche Inc.

Inventor： Oliver POPP ,  Nicola BEAUCAMP ,  Georg DRABNER ,  Stephanie ESSLINGER

IPC: C12P21/00 ,  C07K16/00 ,  C12N1/38

CPC classification number: C12P21/005 ,  C07K16/00 ,  C12N1/38 ,  C07K2317/41

Abstract: The present invention relates to methods for selecting between conditions which enhance cell growth or biomass generation and conditions which affect the N-glycosylation maturity of expressed glycoprotein produced by eukaryotic cells under fermentation culture conditions. Thus, in the methods of the present invention, the glycoprotein producing cells are cultured in a medium which is tailored to a desired end result. The invention also embraces the medium and the use thereof.

公开(公告)号：US12102681B2

公开(公告)日：2024-10-01

申请号：US17669891

申请日：2022-02-11

Applicant: Merck Sharp & Dohme LLC

Inventor： Linda Liang ,  Laurence Fayadat-Dilman ,  Rene De Waal Malefyt ,  Gopalan Raghunathan

IPC: A61K39/395 ,  A61K45/06 ,  C07K16/28 ,  A61K39/00

CPC classification number: A61K39/39566 ,  A61K39/395 ,  A61K45/06 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2896 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/24 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/50 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.

公开(公告)号：US20240301075A1

公开(公告)日：2024-09-12

申请号：US18651896

申请日：2024-05-01

Applicant: Chugai Seiyaku Kabushiki Kaisha

Inventor： Tomoyuki Igawa ,  Shinya Ishii ,  Atsuhiko Maeda ,  Mika Sakurai ,  Tetsuo Kojima ,  Tatsuhiko Tachibana ,  Hirotake Shiraiwa ,  Hiroyuki Tsunoda ,  Yoshinobu Higuchi

IPC: C07K16/28 ,  A61K39/00 ,  C07K16/46

CPC classification number: C07K16/2866 ,  C07K16/461 ,  A61K39/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions.
The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.

公开(公告)号：US20240294672A1

公开(公告)日：2024-09-05

申请号：US18590651

申请日：2024-02-28

Applicant: Chugai Seiyaku Kabushiki Kaisha

Inventor： Junichi Nezu ,  Takahiro Ishiguro ,  Atsushi Narita ,  Akihisa Sakamoto ,  Yumiko Kawai ,  Tomoyuki Igawa ,  Taichi Kuramochi

IPC: C07K16/46 ,  A61K39/00 ,  C07K16/28 ,  C07K16/30

CPC classification number: C07K16/46 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/303 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30

Abstract: Disclosed are bispecific antibodies with heavy chain constant regions having the sequence of an IgG1 constant region with one or more mutations including one or more substitutions that reduce the ability of the heavy chain constant regions to bind to a human Fcγ receptor.

公开(公告)号：US12077602B2

公开(公告)日：2024-09-03

申请号：US16969189

申请日：2018-08-08

Applicant: Beijing SIG Biopharmaceutical Technology Co., Ltd.

Inventor： Xiaoyan Qiu ,  Jingshu Tang ,  Zhi Yang ,  Chong Wang ,  Jingxuan Zhang ,  Hua Zhu ,  Zihan Geng ,  Yang Liu ,  Wenhua Jiang ,  Jing Huang

IPC: C07K16/42 ,  G01N33/68

CPC classification number: C07K16/4283 ,  G01N33/6854 ,  C07K2317/41 ,  C07K2317/522 ,  G01N2333/70546 ,  G01N2333/91148

Abstract: IgG epitope and applications thereof as a target are provided. The IgG epitope is the CH1 domain of non-B cell-derived IgG, and there is N-glycosylated sialic acid modification at the Asn162 site of the domain. The realization of its antigen functions must depend on the sialylation of the site. The present invention further discloses the applications of the IgG epitope as a drug target in preparing drugs for diagnosis and/or treatment of epithelial tumors. In addition, our studies showed that this antigen depends on the sialylation of Asn162 site as a drug target, and the sialylation of this site must depend on sialyltransferase ST3GAL4, indicating that the enzyme can be used as a drug target for preparing tumor therapeutic drugs. Further, integrin β4 is co-expressed and co-localized with IgG containing the epitope. IgG can be used as a marker for preparing drugs for the auxiliary detection of epithelial tumors.

公开(公告)号：US20240279314A1

公开(公告)日：2024-08-22

申请号：US18618981

申请日：2024-03-27

Applicant: The Rockefeller University

Inventor： Jeffrey Ravetch ,  Falk Nimmerjahn ,  Yoshikatsu Kaneko

IPC: C07K16/00 ,  A61K39/00 ,  A61K47/68 ,  C07K16/06 ,  C07K16/18 ,  C12P21/00 ,  G01N33/68

CPC classification number: C07K16/00 ,  A61K47/68 ,  C07K16/06 ,  C07K16/18 ,  C12P21/005 ,  G01N33/6854 ,  A61K2039/505 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/71 ,  C07K2317/76

Abstract: The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a α 2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody.

公开(公告)号：US12065491B2

公开(公告)日：2024-08-20

申请号：US17066401

申请日：2020-10-08

Applicant: Pionyr Immunotherapeutics, Inc.

Inventor： Christopher Chan ,  Aritra Pal ,  Venkataraman Sriram ,  Leonard G. Presta ,  Tiep Tu Le ,  Linda Liang

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K39/00 ,  A61K45/06

CPC classification number: C07K16/2827 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/505 ,  A61K2039/585 ,  A61K45/06 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/92

Abstract: Provided herein are anti-TREM1 antibodies and related methods of making and using anti-TREM1 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM1 antibody or antigen binding fragment thereof.

公开(公告)号：US20240270863A1

公开(公告)日：2024-08-15

申请号：US18597659

申请日：2024-03-06

Applicant: TG Therapeutics, Inc. ,  Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Inventor： George Costas Avgerinos ,  Patrick Michael Hossler ,  Jill A. Myers ,  Yune Z. Kunes

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2887 ,  A61K2039/505 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92

Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.